Prognostic Impact of Performance Status on the Outcomes of Immune Checkpoint Inhibition Strategies in Patients with dMMR/MSI-H Metastatic Colorectal Cancer

Scientists conducted a global study at Tertiary Cancer Centres and collected data of patients with mismatch repair deficient/ microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer treated with anti-programmed-death (PD)-1 monotherapy or anti-PD-1/anti- cytotoxic T-lymphocyte antigen 4 combination.